Kazia Therapeutics Limited Price Chart
Kazia Therapeutics Limited NV9.SG Financial and Trading Overview
| Kazia Therapeutics Limited stock price | 0.94 EUR |
| Previous Close | 0.94 EUR |
| Open | 0.94 EUR |
| Bid | 0.95 EUR x 3000000 |
| Ask | 1.03 EUR x 3000000 |
| Day's Range | 0.94 - 0.94 EUR |
| 52 Week Range | 0.46 - 1.18 EUR |
| Volume | 0 EUR |
| Avg. Volume | 169 EUR |
| Market Cap | 127.82M EUR |
| Beta (5Y Monthly) | 2.269731 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
NV9.SG Valuation Measures
| Enterprise Value | 149.77M EUR |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | Infinity |
| Price/Book (mrq) | 13.239436 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -6.482 |
Trading Information
Kazia Therapeutics Limited Stock Price History
| Beta (5Y Monthly) | 2.269731 |
| 52-Week Change | 100.85% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 1.18 EUR |
| 52 Week Low | 0.46 EUR |
| 50-Day Moving Average | 0.86 EUR |
| 200-Day Moving Average | 0.84 EUR |
NV9.SG Share Statistics
| Avg. Volume (3 month) | 169 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 132.01M |
| Float | 113.81M |
| Short Ratio | N/A |
| % Held by Insiders | 19.28% |
| % Held by Institutions | 14.95% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | June 30, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | June 30, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -43.19% |
| Return on Equity (ttm) | -135.030% |
Income Statement
| Revenue (ttm) | 0 EUR |
| Revenue Per Share (ttm) | 0 EUR |
| Quarterly Revenue Growth (yoy) | -99.70% |
| Gross Profit (ttm) | 10K EUR |
| EBITDA | -23103516 EUR |
| Net Income Avi to Common (ttm) | -25031994 EUR |
| Diluted EPS (ttm) | -0.077 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 4.39M EUR |
| Total Cash Per Share (mrq) | 0.03 EUR |
| Total Debt (mrq) | 552.32K EUR |
| Total Debt/Equity (mrq) | 4.77 EUR |
| Current Ratio (mrq) | 1.06 |
| Book Value Per Share (mrq) | 0.071 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -20177400 EUR |
| Levered Free Cash Flow (ttm) | -14297770 EUR |
Profile of Kazia Therapeutics Limited
| Country | Germany |
| State | NSW |
| City | Sydney |
| Address | Three International Towers |
| ZIP | 2000 |
| Phone | N/A |
| Website | https://www.kaziatherapeutics.com |
| Industry | |
| Sector(s) | |
| Full Time Employees | N/A |
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Australia.
Q&A For Kazia Therapeutics Limited Stock
What is a current NV9.SG stock price?
Kazia Therapeutics Limited NV9.SG stock price today per share is 0.94 EUR.
How to purchase Kazia Therapeutics Limited stock?
You can buy NV9.SG shares on the Stuttgart exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Kazia Therapeutics Limited?
The stock symbol or ticker of Kazia Therapeutics Limited is NV9.SG.
How many shares does Kazia Therapeutics Limited have in circulation?
The max supply of Kazia Therapeutics Limited shares is 135.98M.
What is Kazia Therapeutics Limited Price to Earnings Ratio (PE Ratio)?
Kazia Therapeutics Limited PE Ratio is 0.00000000 now.
What was Kazia Therapeutics Limited earnings per share over the trailing 12 months (TTM)?
Kazia Therapeutics Limited EPS is 0 EUR over the trailing 12 months.